Axis NIFTY Healthcare ETF vs Invesco India Pharma and Healthcare Fund
Direct Plan where a fund has one, Growth option · Data as on 30-10-2026
Axis NIFTY Healthcare ETF is an ETF fund and Invesco India Pharma and Healthcare Fund is a Sectoral fund. Axis NIFTY Healthcare ETF charges 0.45% a year and Invesco India Pharma and Healthcare Fund 3.30%. Their portfolios overlap 40.2%: they hold 7 of the same securities.
Invesco India Pharma and Healthcare Fund
Sectoral
- Expense ratio
- 3.30%
- NAV
- ₹9.66
Which is better, Axis NIFTY Healthcare ETF or Invesco India Pharma and Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Axis NIFTY Healthcare ETF costs less: 0.45% a year against 3.30%.
- Axis NIFTY Healthcare ETF fell less in its worst fall since 10-09-2026: −8.8% against −11.4%.
- Axis NIFTY Healthcare ETF holds more in large companies: 47.8% of the fund in large caps against 29.8%.
- Invesco India Pharma and Healthcare is the larger fund: ₹436 Cr against ₹23 Cr.
- Their portfolios overlap 40.2%: 7 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Axis NIFTY Healthcare ETF | Invesco India Pharma and Healthcare Fund |
|---|---|---|
| Fund house | Axis Mutual Fund | Invesco Mutual Fund |
| Category | ETF | Sectoral |
| AUM | ₹23 Cr (30-09-2026) | ₹436 Cr (30-09-2026) |
| NAV | ₹167.35 | ₹9.66 (Direct) |
| Expense ratio (Direct) | Not available | 3.30% |
| Expense ratio (Regular) | Not available | 5.19% |
| Riskometer | Very High | Very High |
| Benchmark | NIFTY Healthcare TRI | BSE Healthcare TRI |
| Launch date | 17-05-2021 | 01-09-2026 |
| Minimum investment | 50000 (Units) | Not available |
| Lock in | None | None |
| Fund managers | Nandik Malik, Rohit Gautam | Aditya Khemani |
| Exit load | N/A | Exit load of 0.50%, if redeemed within 3 months. |
Axis NIFTY Healthcare ETF vs Invesco India Pharma and Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Axis NIFTY Healthcare ETF | +1.90% | −1.58% | +10.36% | +11.09% | +21.10% | +14.16% | -- |
| Invesco India Pharma and Healthcare Fund (Direct) | +0.73% | -- | -- | -- | -- | -- | -- |
| Sectoral average | −1.70% | -- | -- | -- | -- | -- | -- |
Category average: the average of the 20 Sectoral funds, same plan type.
Axis NIFTY Healthcare ETF vs Invesco India Pharma and Healthcare: Year-wise Returns
| Year | Axis NIFTY Healthcare ETFAxis NIFTY Healthcare ETF | Invesco India Pharma and HealthcareInvesco India Pharma and Healthcare |
|---|---|---|
| 2026to date | +12.54% | -- |
| 2025 | −1.84% | -- |
| 2024 | +40.85% | -- |
| 2023 | +33.48% | -- |
| 2022 | −10.32% | -- |
Axis NIFTY Healthcare ETF vs Invesco India Pharma and Healthcare: Rolling Returns
Every holding period of both funds, against Nifty Healthcare Index TRI, the benchmark of Axis NIFTY Healthcare ETF
Axis NIFTY Healthcare ETF vs Invesco India Pharma and Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Axis NIFTY Healthcare ETF | Invesco India Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +13.53% | −23.45% |
| Standard deviation | 14.80% | 18.70% |
| Sharpe ratio | 0.54 | -1.54 |
| Sortino ratio | 0.77 | -2.20 |
| Maximum drawdown | −20.7% (17-06-2022) | −11.4% (23-10-2026) |
| Beta | 1.00 | 1.00 |
| Alpha | −0.37% | −8.00% |
From daily NAVs, 21-05-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Axis NIFTY Healthcare ETF
Invesco India Pharma and Healthcare Fund (Direct)
Nifty Healthcare Index TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Axis NIFTY Healthcare ETF | −8.8% | 23-09-2026 | 23-10-2026 | Not yet | -- | −2.5% |
| Invesco India Pharma and Healthcare Fund (Direct) | −11.4% | 23-09-2026 | 23-10-2026 | Not yet | -- | −4.4% |
| Nifty Healthcare Index TRI | −8.8% | 23-09-2026 | 23-10-2026 | Not yet | -- | −2.5% |
From daily values since 10-09-2026, the first day every fund has.
Axis NIFTY Healthcare ETF vs Invesco India Pharma and Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: Axis NIFTY Healthcare ETF, September 2026; Invesco India Pharma and Healthcare Fund, September 2026
Holdings in common
- Overlap
- 40.2%
- Held by both
- 7
- Only in Axis NIFTY Healthcare ETF
- 13
- Only in Invesco India Pharma and Healthcare
- 6
| Security | % of Axis NIFTY Healthcare ETF | % of Invesco India Pharma and Healthcare |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 17.00% | 8.99% |
| Divi's Laboratories Limited | 10.44% | 7.85% |
| Apollo Hospitals Enterprise Limited | 7.43% | 8.03% |
| Max Healthcare Institute Limited | 6.12% | 9.58% |
| Torrent Pharmaceuticals Limited | 6.24% | 4.93% |
| Glenmark Pharmaceuticals Limited | 3.11% | 4.86% |
| Krishna Institute Of Medical Sciences Limited | 1.76% | 4.72% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 40.2% means 40.2% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Axis NIFTY Healthcare ETF
| Security | % of fund |
|---|---|
| Laurus Labs Limited | 6.82% |
| Cipla Limited | 6.69% |
| Dr. Reddy's Laboratories Limited | 6.65% |
| Lupin Limited | 4.36% |
| Aurobindo Pharma Limited | 4.08% |
Largest holdings only in Invesco India Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Sai Life Sciences Limited | 8.63% |
| Manipal Health Enterprises Ltd | 7.98% |
| Global Health Limited | 7.00% |
| Dr Agarwals Health Care Limited | 6.32% |
| Corona Remedies Limited | 6.13% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Axis NIFTY Healthcare ETF | Invesco India Pharma and Healthcare |
|---|---|---|
| Equity | 100.0% | 87.0% |
| Debt | 0.0% | 0.0% |
| Cash and others | 0.0% | 13.0% |
Market cap of stocks
| Market cap | Axis NIFTY Healthcare ETF | Invesco India Pharma and Healthcare |
|---|---|---|
| Large Cap | 47.8% | 29.8% |
| Mid Cap | 48.4% | 16.4% |
| Small Cap | 3.8% | 32.8% |
| Not on AMFI's list | 0.0% | 8.0% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Axis NIFTY Healthcare ETF | Invesco India Pharma and Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 81.1% | 41.4% |
| Healthcare Services | 18.9% | 45.6% |
The six largest sectors of each fund's stocks, % of the fund.
Axis NIFTY Healthcare ETF vs Invesco India Pharma and Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Axis NIFTY Healthcare ETF | Invesco India Pharma and Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | Not available | 3.30% |
| Base expense ratio (Direct) | 0.00% | 0.50% |
| Total expense ratio (Regular) | Not available | 5.19% |
| Base expense ratio (Regular) | 0.33% | 2.10% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Invesco India Pharma and Healthcare with
- Invesco India Pharma and Healthcare vs DSP Healthcare
- Invesco India Pharma and Healthcare vs Nippon India Pharma
- Invesco India Pharma and Healthcare vs Bandhan Transportation and Logistics
- Invesco India Pharma and Healthcare vs Nippon India Power & Infra
- Invesco India Pharma and Healthcare vs Invesco India Financial Services
Axis NIFTY Healthcare ETF vs Invesco India Pharma and Healthcare Fund: Frequently Asked Questions
What is the difference between Axis NIFTY Healthcare ETF and Invesco India Pharma and Healthcare Fund?
Axis NIFTY Healthcare ETF is an ETF fund, Invesco India Pharma and Healthcare Fund is a Sectoral fund, run by Axis Mutual Fund and Invesco Mutual Fund. Their portfolios overlap 40.2%. Axis NIFTY Healthcare ETF charges 0.45% a year and Invesco India Pharma and Healthcare Fund 3.30%.
Which has the lower expense ratio, Axis NIFTY Healthcare ETF or Invesco India Pharma and Healthcare Fund?
Axis NIFTY Healthcare ETF charges less: 0.45% a year against 3.30%. These are the total expense ratios reported to AMFI.
How much do Axis NIFTY Healthcare ETF and Invesco India Pharma and Healthcare Fund overlap?
40.2%. They hold 7 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, APOLLOHOSP. From each fund's latest monthly portfolio.
Which is riskier, Axis NIFTY Healthcare ETF or Invesco India Pharma and Healthcare Fund?
On SEBI's riskometer, Axis NIFTY Healthcare ETF is rated Very High and Invesco India Pharma and Healthcare Fund Very High. Over their common history, the standard deviation of daily returns was 14.80% and 18.70% a year.
Can I invest in both Axis NIFTY Healthcare ETF and Invesco India Pharma and Healthcare Fund?
Yes. 40.2% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages Axis NIFTY Healthcare ETF and Invesco India Pharma and Healthcare Fund?
Axis NIFTY Healthcare ETF: Nandik Malik, Rohit Gautam. Invesco India Pharma and Healthcare Fund: Aditya Khemani.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.